Objectives To evaluate the steroid-sparing potential of afimetoran, an equipotent, dual antagonist of TLR7 and TLR8, currently in clinical development for SLE and cutaneous lupus erythematosus ... It ...
Background Between 80–90% of patients with systemic lupus erythematosus (SLE) report fatigue to be the single most troublesome and debilitating symptom of their illness. 1 Recent studies have found ...
Surprising Mechanism of Lupus Kidney Damage Identified Aug. 14, 2024 — A team defined key cells behind severe kidney damage in lupus. The research can inform future antibody ... Eating More ...